SCHEMBL3328409

SCHEMBL3328409

CC(C)(C)OC(=O)N1CC(c2ccc3[nH]ncc3c2)C1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.49
PDE4B Q07343 4/20 0.45
FASN P49327 1/20 0.44
ROCK2 O75116 2/20 0.43
POLB P06746 1/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
NR1H2 P55055 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PIK3CA P42336 1/20 0.41
ACACB O00763 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9952336 0.89 FASN (0.52) PIK3CDPDE4BFASNROCK2IDO1
SCHEMBL22608970 0.82 PDE4B (0.57) PIK3CDPDE4BIDO1TDO2KDM4E
SCHEMBL1016278 0.82 PIK3CD (0.50) PIK3CDPDE4BFASNROCK2CCNC
SCHEMBL1016279 0.82 PIK3CD (0.50) PIK3CDPDE4BFASNROCK2CCNC
SCHEMBL27774785 0.81 SLC6A2 (0.44) PIK3CDFASNROCK2POLBCCNC
SCHEMBL3327513 0.81 PDE4B (0.47) PDE4BKDM4EPIK3CA
SCHEMBL1016108 0.80 PIK3CD (0.49) PIK3CDPDE4BFASNROCK2CCNC
SCHEMBL1016106 0.80 PIK3CD (0.49) PIK3CDPDE4BFASNROCK2CCNC
SCHEMBL24365925 0.80 CCNC (0.54) PIK3CDFASNROCK2POLBCCNC
SCHEMBL29477584 0.78 PRMT5 (0.58) PIK3CDROCK2POLBCCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US disclosed
EP-2155724-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-02-24 EP disclosed
WO-2008116833-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C PIK3CD 4489/4885PDE4B 3245/4885FASN 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.